Compare OMF & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OMF | ERAS |
|---|---|---|
| Founded | 1920 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 6.3B |
| IPO Year | 2013 | 2021 |
| Metric | OMF | ERAS |
|---|---|---|
| Price | $62.61 | $16.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | ★ $66.75 | $14.25 |
| AVG Volume (30 Days) | 768.9K | ★ 3.4M |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.25% | N/A |
| EPS Growth | ★ 54.72 | 36.23 |
| EPS | ★ 1.93 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $66.43 | N/A |
| Revenue Next Year | $6.97 | N/A |
| P/E Ratio | $32.43 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $45.78 | $1.53 |
| 52 Week High | $71.93 | $24.28 |
| Indicator | OMF | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 45.80 | 38.62 |
| Support Level | $61.78 | $12.36 |
| Resistance Level | $62.55 | $19.13 |
| Average True Range (ATR) | 1.27 | 1.29 |
| MACD | -0.20 | -0.25 |
| Stochastic Oscillator | 24.02 | 10.30 |
OneMain Holdings Inc is a consumer finance company providing loan products to customers through its branch network and the internet. The company provides personal loan products; offers credit cards; offers optional credit insurance and others; offers a customer-focused financial wellness program, and acquisitions and dispositions of assets and businesses. It provides origination, underwriting, and servicing of personal loans to non-prime customers. The company operates in single reportable segment Consumer and Insurance which originates and services personal loans and auto finance loans, offer credit cards, and provide optional credit and non-credit insurance and other optional products through its branch and central operations, as well as digital platform.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.